Clinical Trial Update: A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AG-348 (mitapivat) for efficacy and safety in not regularly transfused adults with pyruvate kinase deficiency has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyruvate Kinase Deficiency

Drugs mentioned

• AG-348 (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | Status: COMPLETED | Results posted: 2022-05-24